Proteocyte AI

Home
Canada
Toronto, ON
Proteocyte AI

A Canadian molecular diagnostics company with a novel technology that determines the risk of a head

Better cancer diagnostics

Our novel diagnostic technology, Straticyte™, determines the risk of a head and neck lesion becoming cancerous in the near future. If the risk is high, clinicians can provide early interventions. Clinicians can follow-up effectively with moderate and low risk lesions. Accurate early diagnosis and treatment will drastically improve the clinical outcomes and quality of life for people with head and neck cancer.

05/26/2026

Transform how you manage oral precancer patients.

STRATICYTE® provides clinicians with an objective, AI-driven 5-year oral cancer risk assessment, helping to identify which dysplastic lesions may require closer surveillance or earlier intervention.

By supplementing traditional histopathology, STRATICYTE® supports more informed, confident, and personalized patient management.

Better risk insight leads to better decisions.

Learn how STRATICYTE® can support your practice:
👉 https://proteocyte.com/straticyte/

American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

05/21/2026

What if we could identify high-risk lesions at the earliest possible stage?

In our recent webinar, we explored how earlier risk identification—supported by real patient examples—can change the trajectory of care.

When clinicians have clearer insight into which lesions are more likely to progress, they can act sooner—potentially improving outcomes while reducing unnecessary interventions.

STRATICYTE® helps make this possible by providing an objective, personalized risk assessment to guide decision-making.

Watch the full webinar :
👉 https://vimeo.com/1166776243/70fe5d4b60

Nova Scotia Dental Association Ontario Dental Association Ontario Society of Oral and Maxillofacial Surgery The Terry Fox Foundation The Princess Margaret Cancer Foundation

05/19/2026

Founded in 2011, Proteocyte AI is building a platform of solutions to predict cancer risk.

By leveraging key biomarkers, proprietary algorithms, advanced imaging, and digital pathology, we go beyond traditional diagnostics to deliver deeper insight into individual patient risk.

Our mission is simple:
Enable earlier detection. Support better decisions. Improve patient outcomes.

Learn about our innovative STRATICYTE® test and how it accurately predicts risk of oral cancer:
👉 https://proteocyte.com

Canadian Dental Association Canadian Partnership Against Cancer Société de recherche sur le cancer / Cancer Research Society Fondation québécoise du cancer Manitoba Dental Association NB Dental Society Newfoundland and Labrador Dental Association

05/12/2026

What is the STRATICYTE® test—and how does it help?

STRATICYTE® uses biomarker analysis, digital pathology, and AI-driven algorithms to go beyond traditional histology—delivering an objective, personalized 5-year oral cancer risk score.

Instead of relying on subjective grading alone, clinicians gain clearer insight into which lesions may require closer monitoring or earlier intervention.

It’s a new layer of intelligence in oral cancer risk assessment—supporting more informed, confident decisions.

Watch the full webinar:
👉 https://vimeo.com/1166776243/70fe5d4b60

Alberta Dental Association Association des chirurgiens dentistes du Québec - ACDQ BC Cancer Foundation BC Dental Association CancerCare Manitoba Canadian Association of Oral and Maxillofacial Surgeons Canadian Cancer Society

05/07/2026

Take charge of your oral health.

If you’ve been diagnosed with an oral lesion, understanding your risk matters.

STRATICYTE® is designed to help assess your personalized risk of developing oral cancer, giving your healthcare provider more information to guide your care.

Early insight can lead to earlier action—and better outcomes.

Start the conversation with your provider and take an active role in your health.

Learn more about STRATICYTE®:
👉 https://proteocyte.com/straticyte/patients/

Seattle Jaw Surgery Society of OMS Administrators SPOHNC Mouth Cancer Foundation Osteology Foundation Oral Health Foundation SurgeOn Events

05/05/2026

Where is Oral Cancer Care headed?

Toward a more objective and reproducible approach to predicting malignant transformation.

Oral squamous cell carcinoma (OSCC) often develops from lesions that are difficult to assess with certainty. Traditional histopathology alone can be subjective and inconsistent, leaving gaps in risk prediction.

That’s where risk stratification must evolve.

STRATICYTE® supplements histology with AI-driven biomarker analysis and digital pathology, delivering an objective, personalized 5-year oral cancer risk score—helping clinicians better identify which lesions may progress.

More clarity. More consistency. Better decisions.

Watch the full webinar:
👉 https://vimeo.com/1166776243/70fe5d4b60

American Dental Association Beacon Oral & Maxillofacial Surgeons Everyday Oral Surgery Head and Neck Cancer Alliance Osteo Science Foundation Oral Cancer Foundation Paradigm Oral Health

04/27/2026

Thank you to the American Academy of Oral Medicine (AAOM) and everyone who joined us at the 2026 AAOM Annual Conference.

Proteocyte AI was proud to participate as a Platinum Sponsor, connect with colleagues across the oral medicine community, and share our research on:

“Identifying Malignant Transformation Risk of Dysplastic Oral Lesions with STRATICYTE®”

Special thanks to Dr. Paras B. Patel for presenting our poster and contributing to the discussion around advancing biomarker-guided diagnostics in oral cancer risk prediction.

Events like AAOM help foster collaboration and innovation across the field—and we’re grateful to everyone who stopped by the Proteocyte AI booth to connect with our team.

Learn more about STRATICYTE®:
https://proteocyte.com/straticyte/

American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

04/24/2026

Attending the AAOM Annual Conference this week?

Stop by the Proteocyte AI booth to learn how STRATICYTE® is helping clinicians better understand oral cancer risk in for oral potentially malignant disease (OPMD) patients.

We look forward to connecting with colleagues across oral medicine and discussing the future of precision diagnostics in oral cancer risk prediction.

Learn more about STRATICYTE®:
https://proteocyte.com/straticyte/

American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

04/23/2026

Histology alone is not enough.

For patients with oral potentially malignant disorders (OPMDs), traditional dysplasia grading remains limited—often falling short in reliably predicting which lesions will progress to cancer. With reported sensitivity ranging from 38–89% ¹, variability and uncertainty can impact clinical decision-making.

STRATICYTE® is redefining early risk prediction.

By combining AI-driven biomarker analysis with digital pathology, STRATICYTE® goes beyond the limitations of histologic grading to deliver an objective, personalized 5-year oral cancer risk score.

With 97% sensitivity and negative predictive value²,³,STRATICYTE® provides clinicians with greater confidence in identifying high-risk patients earlier—while helping reduce uncertainty for those at low risk.

The result:
✔️ More precise risk stratification
✔️ Earlier, more proactive intervention
✔️ Better-informed patient management

As the landscape of oral cancer care evolves, STRATICYTE® continues to set a new standard—bringing clarity where traditional methods fall short.

👉 Learn more: https://proteocyte.com/straticyte/
1. Banoczy (1976), Lumerman (1995), Holmstrup (2006), Ardunio (2009), Bradley (2010), Warnakulasuriya (2011), Ho (2012), Zhang (2012,) Sperandio (2013), Dost (2014)
2. Hwang et al, "Individualized five-year risk assessment for oral premalignant lesion progression to cancer." JOOO MAR-2017; Vol 123(3):p374-38. ePub 2016-NOV-22.
3. Darling et al, "Assessing Oral Epithelial Dysplasia Risk for Transformation to Cancer: Comparison Between Histologic Grading Systems Versus S100A7 Immunohistochemical Signature-based Grading." AIMM, Vol 31(6):p399-405, JUL-2023

Alberta Dental Association Association des chirurgiens dentistes du Québec - ACDQ BC Cancer Foundation BC Dental Association CancerCare Manitoba Canadian Association of Oral and Maxillofacial Surgeons Canadian Cancer Society

04/15/2026

Proteocyte AI is proud to be a Platinum Sponsor of the 2026 AAOM Annual Conference.

Our team will be on-site at the Proteocyte AI booth, connecting with leaders in oral medicine and sharing how STRATICYTE® is helping advance risk stratification for dysplastic oral lesions.

We are also pleased to present our accepted abstract:

“Identifying Malignant Transformation Risk of Dysplastic Oral Lesions with STRATICYTE®"

The poster will be presented by Dr. Paras B. Patel, Oral and Maxillofacial Pathologist, Dallas, TX and Principal US Lab Director at Proteocyte AI.

If you're attending AAOM, we invite you to stop by our booth and connect with our team to learn more about STRATICYTE® and the future of biomarker-guided oral cancer risk prediction.

Learn more:
https://proteocyte.com

Seattle Jaw Surgery Society of OMS Administrators SPOHNC Mouth Cancer Foundation Osteology Foundation Oral Health Foundation SurgeOn Events

Address

Toronto, ON
M5G1L7

Website

https://proteocyte.com/

Alerts

Be the first to know and let us send you an email when Proteocyte AI posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.